Research & Clinical Trials
TORL BioTherapeutics Reports 45.5% Response Rate for Ixotatug Vedotin in Germ Cell Tumors
By News Desk ·
Key takeaways
- Ixotatug vedotin monotherapy produced an objective response rate of 45.5% and a disease control rate of 72.7% in 11 heavily pretreated patients with recurrent germ cell tumors.
- Three of six patients whose disease progressed after high-dose chemotherapy and autologous stem cell transplantation achieved confirmed responses.
- Median progression-free survival was 5.8 months, with one patient maintaining a response for 47.4 months.
TORL BioTherapeutics reported preliminary data showing ixotatug vedotin monotherapy produced an objective response rate of 45.5% in 11 heavily pretreated patients with recurrent germ cell tumors. The clinical-stage oncology company presented the results from its Phase 1 CATALINA-1 study at the ESMO Congress 2026 in Madrid, PR Newswire reported on October 23, 2026.
Ixotatug Vedotin's Results in the CATALINA-1 Study
The CATALINA-1 study evaluated ixotatug vedotin, an antibody-drug conjugate targeting Claudin 6, in patients with advanced solid tumors. The germ cell tumor cohort included 11 patients with previously treated advanced or metastatic disease: nine testicular, one ovarian, and one extragonadal. Patients received ixotatug vedotin monotherapy at doses ranging from 0.4 to 3.4 mg/kg every three weeks.
The objective response rate was 45.5%, comprising five partial responses, with responses observed at dose levels from 1 mg/kg to 3.4 mg/kg. The disease control rate was 72.7%. Three of six patients who had received prior high-dose chemotherapy with autologous stem cell transplantation achieved a confirmed response. Median progression-free survival was 5.8 months, and one patient maintained a response for 47.4 months.
"The responses observed with Ixo-V, including in patients whose disease progressed following high-dose chemotherapy and stem cell transplantation, are especially encouraging and suggest the potential to meaningfully improve outcomes for patients with this difficult-to-treat disease," said Eric Sievers, M.D., Chief Medical Officer of TORL BioTherapeutics.
TORL BioTherapeutics' Funding and Leadership
According to akta.pro company records, TORL BioTherapeutics closed a $96 million Series C financing in October 2025 to fund Phase 1 and Phase 2 development of ixotatug vedotin. The company has raised over $450 million from global biotechnology investors as of May 2026. The same records show Aran Maree, M.D. was promoted from Chief Medical Officer to Chief Executive Officer effective May 2026, while Mark Alles transitioned to Board Chairman.
Earlier Ixotatug Vedotin Presentations and Appointments
In June 2026, TORL BioTherapeutics presented preliminary Phase 1 safety and efficacy data for ixotatug vedotin in combination with bevacizumab in recurrent ovarian cancer at the ESMO Gynaecological Cancers Congress 2026, according to Aijourn. PR Newswire reported in May 2026 that the company appointed Aran Maree, M.D. as Chief Executive Officer and Board Member, effective May 1, 2026, succeeding Mark Alles, who continued as Board Chairman. In October 2026, PR Newswire reported that TORL BioTherapeutics appointed Sandip Kapadia as CFO and Eric Sievers as CMO, completing a year-long leadership expansion, and announced Mark Alles' retirement as Chairman, with him remaining a strategic advisor.
CATALINA-2 Data Expected in 2027
According to akta.pro company records, TORL BioTherapeutics initiated the global, randomized CATALINA-2 registrational Phase 2 study of ixotatug vedotin in CLDN6-positive platinum-resistant ovarian cancer in December 2024, with topline data anticipated mid-2027.